Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STADA Arzneimittel AG M&A Activity 2002

Jan 8, 2002

412_rns_2002-01-08_028abd07-50a0-423f-bfc9-5a4fb5f06b28.html

M&A Activity

Open in viewer

Opens in your device viewer

News Details

Ad-hoc | 8 January 2002 07:55

STADA Arzneimittel AG english

STADA is on track to expand U.S. business Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STADA Arzneimittel AG has acquired a generic product range with sales volume of 4 million USD for its US subsidiary. The product range acquired from ESI Lederle on 28/12/2001 includes 81 approvals for generics (so-called ANDAs) and 11 pending ANDAs for various indications. With this acquisition STADA is on track to continue the planned expansion of its marketing and sales company in the U.S., the largest market for generics in the world. The first step was the take-over of operations of Mova Laboratories with a sales volume of 26 million USD, effective on 01/01/2002. For 2002 STADA now anticipates U.S. sales of approx. 38 million Euro (over 33 million USD) and targets further expansion of its U.S. business by means of additional product acquisitions. STADA Arzneimittel AG, listed in the MDAX, achieved record sales in 2001. By September 30, 2001, sales increased by +15% to 404 million Euro, EBITDA by +58% to 61.4 million Euro. For 2001 STADA expects group sales of well in excess of 500 million Euro after already reaching group sales of 511.3 million Euro (= 1 billion DM) by the first days of December. In addition to its existing European sales network and the recent U.S. activities, STADA has been expanding its sales network in Asia over the last few years. For additional information, please contact: STADA Arzneimittel AG / Corporate Communications / 61118 Bad Vilbel Tel.: +49(0) 6101 603 -113 / Fax: +49(0) 6101 603 506 /E-mail: [email protected] or visit our web-site at www.stada.de. end of ad-hoc-announcement (c)DGAP 08.01.2002 ——————————————————————————– WKN: 725180; ISIN: DE0007251803; Index: MDAX Listed: Amtlicher Handel in Frankfurt und Düsseldorf; Freiverkehr in Berlin, Bremen, Hamburg, München und Stuttgart 080755 Jän 02